

\$2.48m Received Under the Rights Issue

Transformative, predictive cancer diagnostics technology company, Rhythm Biosciences Ltd (ASX: RHY) (**Rhythm** or the **Company**) advises its pro-rata non renounceable rights issue (**Rights Issue**) as announced on 9 February 2024 closed at 5pm AEDT on 14 March 2024.

The Company reports that approximately \$2.48m in cash has been received under the Rights Issue and thanks participating shareholders for their continued support. A summary of acceptances and funds raised is provided here:

	New Shares*	New Options*	Funds \$
Maximum under the Rights Issue	66,342,777	33,171,389	\$6,634,278

Entitlement acceptances under the Rights Issue	16,195,109	8,097,555	\$1,619,511
Top-Up Facility acceptances up under the Rights Issue	5,027,782	2,513,891	\$502,778
Total acceptances under the Rights Issue	21,222,891	10,611,446	\$2,122,289

Partial Underwriting of Shortfall Offer	3,616,580	1,808,290	\$361,658
Total received under the Rights Issue Offer	24,839,471	12,419,736	\$2,483,947

Balance maximum remaining shortfall under the Rights Issue	41,503,306	20,751,653	\$4,150,331
---	-------------------	-------------------	--------------------

* The number of New Shares and New Options is subject to rounding.

The Rights Issue was partially underwritten by entities associated with the Executive Chair of the Company, Mr Otto Buttula. The Company is currently working with PAC Partners Securities Pty Limited (**PAC Partners**) to place the remaining shortfall shares (41,503,306). A commitment book to subscribe for the Shortfall Offer has commenced, with numerous new and existing shareholders expressing interest. The Company has up to 3 months of the Rights Issue closing date to close this Offer.

Allotment of shares and options under the Rights Issue Offer will take place today, 21 March 2024 with expected normal trading of New Shares issued on 22 March 2024 in accordance with the previously advised timetable. Parties seeking to commit to participating in the take-up of Shortfall Shares from Rhythm's Rights Issue Offer should register their interest with PAC Partners principal Sean Kennedy at corporate@pacpartners.com.au.

- ENDS -

Authorised for release by the Board.

For further information contact us via investor@rhythmbio.com:

Mr. Otto Buttula Executive Chairman	Mr. Guy Carisbrooke Financial Controller	Mr. James Barrie Joint Company Secretary
---	--	--

About Rhythm Biosciences

Rhythm Biosciences Ltd (ASX: RHY) is an Australian innovative, medical diagnostics company aimed at delivering simple, affordable blood tests for accurate and early detection of cancers. Rhythm is focused on improving patient outcomes through detection at the earliest possible stage, reducing the global burden of cancer and saving lives.

Rhythm Biosciences is committed to working with likeminded global partners to achieve commercialisation and distribution of these simple solutions.

The company was founded in 2017 and is headquartered in Melbourne, Australia. For more information, visit rhythmbio.com and follow the company on LinkedIn and Twitter.

About ColoSTAT[®]

Colorectal cancer (CRC), also referred to as bowel cancer, is the second leading cause of cancer deaths globally. If diagnosed early, colorectal cancer is curable.

The ColoSTAT[®] Test-Kit is Rhythm Bioscience's simple blood test for the detection of CRC. It measures five specific protein biomarkers that indicate the likelihood presence of CRC. The test can be used as an alternative for individuals who are unable or unwilling to participate in current screening programs.

The ColoSTAT[®] Test-Kit is based on research from Australia's CSIRO and is patent protected internationally. It has the potential to play a key role in reducing the mortality rate and healthcare costs associated with colorectal cancer.